Home/Filings/4/0001225208-11-015859
4//SEC Filing

Hanson John M 4

Accession 0001225208-11-015859

CIK 0001405197other

Filed

Jun 2, 8:00 PM ET

Accepted

Jun 3, 2:14 PM ET

Size

14.8 KB

Accession

0001225208-11-015859

Insider Transaction Report

Form 4
Period: 2011-06-01
Hanson John M
Executive VP & CFO
Transactions
  • Disposition to Issuer

    Common Stock

    2011-06-0189,3310 total
  • Disposition to Issuer

    Options (right to buy)

    2011-06-0126,3600 total
    Exercise: $11.00From: 2009-04-01Exp: 2018-04-01Common Stock (26,360 underlying)
  • Disposition to Issuer

    Options (right to buy)

    2011-06-01421,7600 total
    Exercise: $1.39From: 2006-04-01Exp: 2015-11-10Common Stock (421,760 underlying)
  • Disposition to Issuer

    Options (right to buy)

    2011-06-01105,4400 total
    Exercise: $11.00From: 2007-04-01Exp: 2016-12-06Common Stock (105,440 underlying)
  • Disposition to Issuer

    Options (right to buy)

    2011-06-0135,2660 total
    Exercise: $19.00Exp: 2019-09-30Common Stock (35,266 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to the merger agreement between Issuer, Stream Merger Sub, Inc., Grifols, S.A., and Grifols, Inc. in exchange for $19.00 in cash and 0.6485 non-voting (Class B) ordinary shares of Grifols, S.A. (the Grifols B shares) (in the form of American Depository Shares (the Grifols ADS); with each Grifols ADS representing one-half of one Grifols B share) per Issuer share, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.
  • [F2]This option, which provided for vesting in three equal annual installments beginning April 1, 2011, deemed subject to a cashless exercise pursuant to the merger agreement, and the net number of Issuer shares deemed issued in connection with the deemed cashless exercise (after taking into account the exercise price of the option and applicable withholding taxes) were disposed of pursuant to the merger agreement in exchange for $19 in cash and 0.6485 Grifols ADSs per Issuer share deemed issued, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.
  • [F3]This option, which was fully vested and exercisable, deemed subject to a cashless exercise pursuant to the merger agreement, and the net number of Issuer shares deemed issued in connection with the deemed cashless exercise (after taking into account the exercise price of the option and applicable withholding taxes) were disposed of pursuant to the merger agreement in exchange for $19 in cash and 0.6485 Grifols ADSs per Issuer share deemed issued, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.

Documents

1 file

Issuer

Talecris Biotherapeutics Holdings Corp.

CIK 0001405197

Entity typeother

Related Parties

1
  • filerCIK 0001472092

Filing Metadata

Form type
4
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 2:14 PM ET
Size
14.8 KB